Coeptis Therapeutics Hldgs I
13F holders, Q4 2024 (December 31)5holders
$5.22avg. 13F price*
At the end of Q4 2024, 5 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings. The largest holders were UBS Group AG ($37K), Tower Research Capital LLC (TRC) ($4K) and Steward Partners Investment Advisory, LLC ($3K).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $44K |
| Exits | 0 | $0 |
Ownership 5 holders
| UBS Group AG | 0.00% | New | 6,765 | $37K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 723 | $4K |
| Steward Partners Investment Advisory, LLC | 0.00% | New | 1,000 | $3K |
| Semmax Financial Advisors Inc. | 0.00% | New | 5 | $62 |
| Bank of America Corp. | 0.00% | New | 11 | $60 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.